Bestgen, B., Jones, S., Thathy, V., Kuemmerle, A., Barcelo, C., Haouala, A., Gossen, D., Marx, M. W., Di Resta, I., Szramowska, M., Webster, R. A., Llewellyn, S., Ritacco, D. A., Yeo, T., Leroy, D., Barber, B. E., Fidock, D. A., Griffin, P., Lickliter, J., & Chalon, S. (2024). Safety, tolerability, pharmacokinetics, and antimalarial activity of MMV533: a phase 1a first-in-human, randomised, ascending dose and food effect study, and a phase 1b Plasmodium falciparum volunteer infection study. The Lancet Infectious Diseases. https://doi.org/10.1016/s1473-3099(24)00664-9